Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
116 hedge funds and large institutions have $354M invested in Keryx Biopharmaceuticals Inc in 2016 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 34 reducing their positions, and 15 closing their positions.
15% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 34
2% less funds holding
Funds holding: 118 → 116 (-2)
12% less call options, than puts
Call options by funds: $3.91M | Put options by funds: $4.44M
13% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 15
19% less capital invested
Capital invested by funds: $439M → $354M (-$85.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$5.69M |
| 2 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$2.23M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
+$2.21M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.91M |
| 5 |
HS
HighVista Strategies
Boston,
Massachusetts
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$4.56M |
| 2 |
Millennium Management
New York
|
-$3.84M |
| 3 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$2.22M |
| 4 |
CCM
Century Capital Management
Boston,
Massachusetts
|
-$1.81M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.36M |
KERX Hedge Fund Activity: Q3 2016 in Review
116 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q3 2016, worth a combined $354M — down 19% from $439M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of KERX and 13 opened new positions — a net loss of 2 holders — while 34 trimmed existing stakes and 39 added.
The largest buyer was State Street, adding an estimated $5.69M. The largest seller was Clough Capital Partners, cutting an estimated $4.56M.
- 116 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q3 2016, down from 118 in Q2 2016.
- Funds reported $354M of Keryx Biopharmaceuticals Inc stock for Q3 2016, down 19% quarter-over-quarter.
- 13 funds opened new Keryx Biopharmaceuticals Inc positions in Q3 2016 and 15 closed out, a net change of -2 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q3 2016 was State Street, an estimated $5.69M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q3 2016 was Clough Capital Partners, an estimated $4.56M sold.
Based on aggregated 13F filings for Q3 2016.